Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Glaukos to $75 from $63 and keeps an Equal Weight rating on the shares. CMS released their 2024 proposed rule for ASC reimbursement and Glaukos saw two large proposed reimbursement increases for iStent and Infinite, which bode well for adoption in 2024 and beyond, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GKOS: